Professor Andrew Tutt
Andrew Tutt qualified in Medicine in 1990. After postgraduate training in General Medicine, he
trained in Clinical Oncology at the Royal Marsden Hospital, before gaining a Doctoral Research
Training Fellowship from the Medical Research Council, to work in Professor Alan Ashworth’s
laboratory at The Institute of Cancer Research.
Here he worked on the then unknown DNA repair functions of the BRCA2 breast cancer
predisposition gene, and described the role of BRCA2 in homologous recombination (HR). He
was awarded his PhD in 2002. In his postdoctoral work as a Clinician Scientist, he identified the
synthetic lethality between PARP inhibitors and BRCA1/2 mutations with Dr Chris Lord and
Professor Alan Ashworth.
He went on to design the single agent PARP inhibitor Proof of Concept Phase I trials and
associated DNA repair biomarker studies with the ICR and Royal Marsden Drug Development
Unit, and has since lead international Phase II and III trials, examining the role of HR directed
therapies including PARP inhibitors and platinums for BRCA1 / BRCA2 deficiency associated
malignancy including; the TNT trial, which changed clinical practice for patients with BRCA1/1
mutated breast cancer.
He cares for women with breast cancer as a Consultant Oncologist, and as a member of the
multidisciplinary Breast Units at Guy’s and St Thomas’ and Royal Marsden NHS Foundation
Trusts. Andrew is also a member of the St Gallen Early Breast Cancer International Consensus
Panel and the Oxford Early Breast Cancer Trialists Cooperative Group (EBCTCG).
He is Professor of Breast Oncology and Director of the Breast Cancer Now Toby Robins Research
Centre, at the Institute of Cancer Research (ICR) and King’s College London, and Head of the
Division of Breast Cancer Research at the ICR.
Andrew leads a clinical trial programme focusing on TNBC and cancers associated with
functional deficiencies in BRCA1 and BRCA2. He also leads translational laboratories at both the
ICR and KCL, studying BRCA1 and BRCA2 associated and Triple Negative forms of breast cancer
(TNBC). Their recent work included new TNBC targets, PIM1 and KIFCI, published in Nature
Medicine and Nature Communications.
Andrew’s group have also published papers from these programmes in the journals Nature, The
New England Journal of Medicine, The Lancet, Nature Medicine, Journal of Clinical Oncology,
Cancer Research, Science Translational Medicine and Cancer Discovery. He is Chief Investigator
for the multicentre UKCRN ”Triple Negative Trial”, recently reported in Nature Medicine, and is
Global Study Chair of the ‘OlympiA’ study – an adjuvant PARP inhibitor trial in patients with
germline BRCA1/2 mutations and breast cancer.
He has been a visiting Professor at British Columbia Cancer Agency, and Jean Lubrano visiting
Scholar at Harvard Medical School. In 2015 he received the Addarii Award for his work in the
field of BRCA1 and BRCA2 associated breast and ovarian cancer research.
Andrew was recently elected to the Fellowship of the Academy of Medical Sciences